Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05360758 |
| Ibrutinib Adapted to Response in Patients With CLL |
| unknown |
| — |
| 80 |
| Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER |
| 0 |
| Dec 28, 2022 |
| clinicaltrials |
| NCT05667402 | Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia | unknown | N/A | 50 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05663983 | Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients | unknown | — | 600 | Campus Bio-Medico UniversityOTHER | 0 | Dec 23, 2022 | clinicaltrials |
| NCT05664230 | Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics(Leucosteo) | unknown | — | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05660993 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | unknown | Phase 2 | 50 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05654766 | Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies | unknown | — | 200 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05649371 | Multiphasic Prehab Allo-HSCT | unknown | N/A | 60 | University of CalgaryOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Kecellitics Biotech Company LtdINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT03709017 | Iclusig PMS in CML or Ph+ALL Patients | unknown | — | 50 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05638763 | Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia | unknown | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT04100187 | Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | unknown | Phase 1 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 1, 2022 | clinicaltrials |
| NCT05632874 | The Effect of Relaxing Breathing Exercise Applied to Patients Before Bone Marrow Biopsy on Vital Signs, Pain and Anxiety Levels | unknown | N/A | 72 | Uskudar UniversityOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01811368 | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 2 | 20 | Joseph TuscanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05291390 | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 200 | Armaceutica, Inc.INDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05626764 | QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management | unknown | — | 3,000 | Hospices Civils de LyonOTHER | 4 | Nov 25, 2022 | clinicaltrials |
| NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | unknown | Phase 1 | 86 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05254821 | Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients | unknown | — | 130 | Federico II UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05610202 | Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects | unknown | Phase 1 | 137 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04481815 | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 240 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04913922 | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML(AARON) | unknown | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05577884 | Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma | unknown | — | 30 | Seoul National University HospitalOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05609227 | Effect of Mobile Application on Supportive Care Needs and Quality of Life Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | N/A | 36 | Baskent UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04899882 | Physical Fitness Impact of Early Physiotherapy Intervention With a Standardized Exercise Therapy Program in Adult Patients Receiving Intensive Induction Chemotherapy for Treatment of Acute Leukemia During Extended Hospitalization.(KinHémo) | unknown | N/A | 150 | University Hospital, AngersOTHER_GOV | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03460522 | Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | unknown | Phase 2 | 65 | Nicola GoekbugetOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05565898 | PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow Infiltration for Initial Staging of Lymphoma | unknown | — | 100 | Assiut UniversityOTHER | 0 | Nov 1, 2022 | clinicaltrials |
| NCT05600959 | Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH | unknown | — | 60 | Beijing Friendship HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05601895 | The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance | unknown | — | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05602051 | Mindfulness-based Virtual Reality Intervention | unknown | N/A | 110 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02643888 | Pre-existing Kinase Domain Mutations in Ph-positive Leukemias | unknown | — | 30 | St. Anna KinderkrebsforschungOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596097 | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | unknown | Phase 2 | 15 | LanZhou UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2023source: clinicaltrials